Does the FDA Accept Clinical Data from Latin America? — bioaccess®
Yes. The FDA accepts clinical data generated outside the United States — including in Latin America — to support US submissions, provided the study meets Good Clinical Practice (GCP) and the FDA can validate the data. Acceptability depends on data quality, not geography.
Eligibility of foreign clinical data for FDA submission does not constitute or predict FDA clearance, approval, or acceptance of any specific application.
The Regulatory Basis
21 CFR 812.28 — FDA acceptance of outside-US investigational medical device data to support an IDE, 510(k), De Novo, or PMA, when conducted under GCP and validatable by the FDA.
21 CFR 312.120 — FDA acceptance of foreign clinical studies of drugs and biologics not conducted under an IND, when conducted under GCP with independent ethics committee review and informed consent.
FDASIA §1123 / ICH E6 GCP — Studies executed to the ICH E6 Good Clinical Practice standard produce data the FDA treats as equivalent in quality to US-generated data.
Population applicability — Data must be applicable to the US patient population; large treatment-naïve Latin American populations can strengthen diversity when designed for it.
What Makes Outside-US Data FDA-Acceptable
Conducted to ICH E6 Good Clinical Practice (GCP) standards
Reviewed and approved by an independent ethics committee (IEC/IRB)
Qualified investigators and adequately monitored sites
Data-integrity controls and source-document verification (SDV)
FDA able to validate data via records access or on-site inspection
Study applicable to the US population and US medical practice
How bioaccess® Engineers FDA-Acceptable Data
FDA Pre-Submission (Pre-Sub) to align on design, endpoints, and data requirements before enrollment
Protocol, consent, monitoring, and data management designed to ISO 14155 (devices) / ICH E6 (drugs) and 21 CFR from day one
Execution with source-document verification, adverse-event reporting, and an inspectable trial master file
Submission packaged with a bridging rationale for applicability to the US population
Proof
bioaccess® has generated first-in-human clinical data in Latin America supporting US regulatory strategy for clients including Axoft, PAVmed, and enVVeno Medical. See case studies.
This is general information, not regulatory advice — confirm your specific pathway with the FDA, ideally via a Pre-Submission.
The question every sponsor asks is whether data generated abroad can support FDA review. It can — when the study satisfies applicable criteria (ISO 14155, independent ethics oversight, and FDA validation), foreign device data may be included in an FDA submission under 21 CFR 812.28. We design every protocol to that standard from day one, so the data holds up under review.